A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer

Dall’Era, 2012, Active surveillance for prostate cancer: a systematic review of the literature, Eur Urol, 62, 976, 10.1016/j.eururo.2012.05.072 Conti, 2009, Pathological outcomes of candidates for active surveillance of prostate cancer, J Urol, 181, 1628, 10.1016/j.juro.2008.11.107 Müntener, 2008, Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy, Eur Urol, 53, 767, 10.1016/j.eururo.2007.11.016 van den Bergh, 2014, Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review, Eur Urol, 65, 1023, 10.1016/j.eururo.2014.01.027 Sartori, 2014, Biomarkers in prostate cancer: what's new?, Curr Opin Oncol, 26, 259, 10.1097/CCO.0000000000000065 Simon, 2009, Use of archived specimens in evaluation of prognostic and predictive biomarkers, J Natl Cancer Inst, 101, 1446, 10.1093/jnci/djp335 Febbo, 2011, NCCN task force report: evaluating the clinical utility of tumor markers in oncology, J Natl Compr Canc Netw, 9, S1, 10.6004/jnccn.2011.0137 McShane, 2012, Publication of tumor marker research results: the necessity for complete and transparent reporting, J Clin Oncol, 30, 4223, 10.1200/JCO.2012.42.6858 Brassell, 2009, The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research, Urol Oncol, 27, 562, 10.1016/j.urolonc.2009.01.023 McShane, 2005, Reporting recommendations for tumor marker prognostic studies (REMARK), J Natl Cancer Inst, 97, 1180, 10.1093/jnci/dji237 Epstein, 2005, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, Am J Surg Pathol, 29, 1228, 10.1097/01.pas.0000173646.99337.b1 Knezevic, 2013, Analytical validation of the Oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies, BMC Genomics, 14, 690, 10.1186/1471-2164-14-690 Klein, 2014, A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling, Eur Urol, 66, 550, 10.1016/j.eururo.2014.05.004 Cookson, 2007, J Urol, 177, 540, 10.1016/j.juro.2006.10.097 Preston, 2011, The prognostic significance of capsular incision into tumor during radical prostatectomy, Eur Urol, 59, 613, 10.1016/j.eururo.2010.12.005 Therneau, 2000 Therneau, 1990, Martingale-based residuals for survival models, Biometrika, 77, 147, 10.1093/biomet/77.1.147 Freedland, 2005, Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy, JAMA, 294, 433, 10.1001/jama.294.4.433 Davis, 2014, Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact, BJU Int, 114, 320 National Comprehensive Cancer Network (NCCN). Prostate cancer (version 1.2015). NCCN Web site. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed November 6, 2014. Badani KK, Kemeter MJ, Febbo PG, et al. The impact of a biopsy-based 17-gene Genomic Prostate Score on treatment recommendations for men with newly diagnosed clinically prostate cancer who are candidates for active surveillance. Urol Pract. In press. http://dx.doi.org/10.1016/j.urpr.2014.10.010 Farrell, 2013, Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men, Int J Mol Sci, 14, 15510, 10.3390/ijms140815510 Rosen, 2012, Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer, Urology, 80, 749, 10.1016/j.urology.2012.07.001 Khani, 2014, Evidence for molecular differences in prostate cancer between African American and Caucasian men, Clin Cancer Res, 20, 4925, 10.1158/1078-0432.CCR-13-2265 Powell, 2013, Genes associated with prostate cancer are differentially expressed in African American and European American men, Cancer Epidemiol Biomarkers Prev, 22, 891, 10.1158/1055-9965.EPI-12-1238 Platz, 2000, Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals, J Natl Cancer Inst, 92, 2009, 10.1093/jnci/92.24.2009 Klein, 2013, Evidence for a field effect in early prostate cancer: gene expression profiles in normal-appearing prostate tissue adjacent to tumor are predictive of clinical outcome [abstract 5029], J Clin Oncol, 31 Schlomm, 2009, Molecular cancer phenotype in normal prostate tissue, Eur Urol, 55, 885, 10.1016/j.eururo.2008.04.105 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013